STAT December 22, 2021
Angus Chen

The holy grail of cancer drug targets is akin to a unicorn horn: a marker that only cancer cells have, clearly distinguishing them from healthy cells. In reality, nearly all cancer drug targets are also found on many healthy cells, leading to serious off-tumor toxicity that — in extreme scenarios — can be fatal.

Synthetic biologist Kobi Benenson might have a way around that. Inside an engineered virus, he and his colleagues at ETH Zurich packaged a programmable genetic circuit that uses multiple targets to build a profile of a cancer cell. Detailed in a mouse study recently published in Science, it’s a nanoscopic biological computer that roams through the body, executing a program that seeks to recognize and kill...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider
Akiko Iwasaki: The Immunology of Covid and the Future
Novartis to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75B
GLP-1 Agonists May One Day Treat Prostate Cancer
Amgen shares soar as executives outline obesity drug push
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

Share This Article